Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201112003 Principal Investigator: Tan, Benjamin
Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Phase: II Disease Site: Liver
Participating Site(s):
 
Main Campus
Map and Directions		 St. Peters
Map and Directions		 West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purpose of this study is to find out if GC33 can help stop the growth and spread of cancer cells in patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC) whose disease has progressed after previous treatment(s) or who have been intolerant to previous treatment(s), and to see if the drug may cause any side effects.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)